PET for staging of Hodgkin's disease and non-Hodgkin's lymphoma

被引:81
作者
Schiepers, Christiaan [1 ]
Filmont, Jean-Emmanuel [1 ]
Czernin, Johannes [1 ]
机构
[1] Univ Calif Los Angeles, David Geffen Sch Med, Ahmanson Biol Imaging Ctr, Dept Mol & Med Pharmacol, Los Angeles, CA 90095 USA
关键词
lymphoma; Hodgkin's disease; non-Hodgkin's lymphoma; primary staging; metabolic imaging; FDG; PET;
D O I
10.1007/s00259-003-1165-6
中图分类号
R8 [特种医学]; R445 [影像诊断学];
学科分类号
1002 ; 100207 ; 1009 ;
摘要
Metabolic or molecular imaging with fluorine-18 fluorodeoxyglucose positron emission tomography (FDG-PET) has emerged as a powerful imaging modality for diagnosis, staging, and therapy monitoring of a variety of cancers. The accuracy of FDG-PET as an imaging tool for the primary staging of lymphoma suffers from the absence of a reference criterion to which all imaging modalities can be compared. For ethical reasons, pathological diagnosis is usually not possible for all of the lesions and abnormalities found. In this article, the current state of the art for staging of primary lymphoma is reviewed and the implications for staging and the impact on patient management discussed. Whole-body PET using FDG is superior to conventional staging, i.e., physical examination, laboratory tests, plain radiography, and CT, by 10-20%. The sensitivity of FDG-PET varies for different regions of the body and appears lowest for infradiaphragmatic disease involvement. Staging with metabolic imaging leads in 10-40% of patients to a change in clinical stage. Highly variable results have been reported on whether up- or downstaging of lymphoma with PET leads to changes in the therapeutic approach for primary lymphoma.
引用
收藏
页码:S82 / S88
页数:7
相关论文
共 41 条
[1]   THE ROLE OF GA-67 IN THE CLINICAL-EVALUATION OF CANCER [J].
BEKERMAN, C ;
HOFFER, PB ;
BITRAN, JD .
SEMINARS IN NUCLEAR MEDICINE, 1984, 14 (04) :296-323
[2]   Magnetic resonance imaging and Ga-67 scan versus computed tomography in the staging and in the monitoring of mediastinal malignant lymphoma: A prospective pilot study [J].
Bendini, M ;
Zuiani, C ;
Bazzocchi, M ;
Dalpiaz, G ;
Zaja, F ;
Englaro, E .
MAGNETIC RESONANCE MATERIALS IN PHYSICS BIOLOGY AND MEDICINE, 1996, 4 (3-4) :213-224
[3]  
Buchmann I, 2001, CANCER, V91, P889
[4]   Detection of lymphoma in bone marrow by whole-body positron emission tomography [J].
Carr, R ;
Barrington, SF ;
Madan, B ;
O'Doherty, MJ ;
Saunders, CAB ;
van der Walt, J ;
Timothy, AR .
BLOOD, 1998, 91 (09) :3340-3346
[5]  
Delbeke D, 1999, J NUCL MED, V40, P591
[6]   Clinical relevance of gallium-67 scintigraphy in lymphoma before and after therapy [J].
Delcambre, C ;
Reman, O ;
Henry-Amar, M ;
Peny, AM ;
Macro, M ;
Cheze, S ;
Génot, JY ;
Tanguy, A ;
Switsers, O ;
Van, HL ;
Couëtte, JE ;
Leporrier, M ;
Bardet, S .
EUROPEAN JOURNAL OF NUCLEAR MEDICINE, 2000, 27 (02) :176-184
[7]  
Front D, 1996, J NUCL MED, V37, P530
[8]   GA-67 SPECT BEFORE AND AFTER TREATMENT OF LYMPHOMA [J].
FRONT, D ;
ISRAEL, O ;
EPELBAUM, R ;
BENHAIM, S ;
SAPIR, EE ;
JERUSHALMI, J ;
KOLODNY, GM ;
ROBINSON, E .
RADIOLOGY, 1990, 175 (02) :515-519
[9]   THE ROLE OF GA-67 SCINTIGRAPHY IN EVALUATING THE RESULTS OF THERAPY OF LYMPHOMA PATIENTS [J].
FRONT, D ;
ISRAEL, O .
SEMINARS IN NUCLEAR MEDICINE, 1995, 25 (01) :60-71
[10]   The continuing clinical role of gallium 67 scintigraphy in the age of receptor imaging [J].
Front, D ;
BarShalom, R ;
Israel, O .
SEMINARS IN NUCLEAR MEDICINE, 1997, 27 (01) :68-74